Home › Anterior Cruciate Ligament Injuries › NCT06511232

Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction

Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction: A Randomized Control Trial

Who can join

Ages 18 to 40 · All sexes

Inclusion Criteria:

* Patients of the IRB approved surgeon(s) undergoing ACL reconstruction with bone-to-bone (BTB) autograft
* Patients aged between 18-40 years old at the time of surgery

Exclusion Criteria:

* Patients undergoing ACL reconstruction with any other type of autograft or allograft other than BTB
* Patients younger than 18 years old or older than 40 years old
* Patients undergoing meniscal root repair or any other repair that changes their weight-bearing status
* Patients with a history of substance abuse
* Vulnerable populations
* Patients on chronic pain medication within the last 6 months
* BMI \>/= 35
* Allergy to morphine
* Unwilling to participate
* Any additional reason the PI deems reasonable

About the study

The purpose of this study is to determine if intraosseous (IO) morphine decreases pain and post-operative opioid use in patients undergoing anterior cruciate ligament (ACL) reconstruction.

What is being tested

• Intraosseous Morphine (drug)

Sponsor: The Methodist Hospital Research Institute · Participants: 84 · Started: Aug 19, 2024

Contact the study team

• Haley Goble, MHA · Phone: 713-441-3930

Official record on ClinicalTrials.gov — NCT06511232

Locations in the U.S.

Conditions

• Anterior Cruciate Ligament Injuries

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.